Literature DB >> 33924482

Evidence-Based Aerobic Exercise Training in Metabolic-Associated Fatty Liver Disease: Systematic Review with Meta-Analysis.

Joanna Słomko1, Marta Zalewska2, Wojciech Niemiro3,4, Sławomir Kujawski1, Maciej Słupski5, Beata Januszko-Giergielewicz5, Monika Zawadka-Kunikowska1, Julia Newton6, Lynette Hodges7, Jacek Kubica8, Paweł Zalewski1.   

Abstract

BACKGROUND: This meta-analysis evaluates the overall effect of the non-pharmacological intervention, aerobic exercise, upon serum liver enzymes levels, glucose metabolism and anthropometric measures amongst patients with metabolic associated fatty liver disease (MAFLD). It also examines whether the effects on these outcomes are moderated by the aerobic training protocol when considered according to the American College of Sports Medicine (ACSM) recommended FITT (frequency, intensity, time, type) principles. Approach and
Results: Fifteen randomized control trials were included in the meta-analysis. Compared with usual care, continuous and interval training showed significant efficacy in alanine aminotransferase (ALT) level improvement (MD = -2.4, 95% CI: -4.34 to -0.46 p = 0.015, I2 = 9.1%). Interventions based on all types of aerobic exercise protocols showed significant improvement of intrahepatic triglycerides (MD = -4.0557, 95% CI: -5.3711 to -2.7403, p < 0.0001, I2 = 0%) and BMI (MD = -0.9774, 95% CI: -1.4086 to -0.5462, p < 0.0001, I2 = 0). Meta-regression analysis demonstrated a significant correlation between total intervention time and ALT level (for all aerobic protocols: 6.0056, se = 2.6896, z = 2.2329, p = 0.02; as well as for continuous and interval aerobic protocols: 5.5069, se = 2.7315, z = 2.016, p = 0.04).
CONCLUSIONS: All types of aerobic exercise protocols are effective at improving intrahepatic triglycerides and lead to a reduction in body mass index. In addition, continuous and interval aerobic exercise may be more effective at improving ALT ≤12 weeks intervention time benefits the management of MAFLD.

Entities:  

Keywords:  aerobic activity; exercise; fatty liver; metabolic fatty liver; treatment

Year:  2021        PMID: 33924482     DOI: 10.3390/jcm10081659

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  5 in total

Review 1.  Exercise Prescription Intervention Rehabilitation Suggestions for Fatty Liver Patients.

Authors:  Tian Wan; Kun-Da Hong; Si-Yu Lu
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-16       Impact factor: 2.650

2.  Effect of Different Types of Intermittent Fasting on Biochemical and Anthropometric Parameters among Patients with Metabolic-Associated Fatty Liver Disease (MAFLD)-A Systematic Review.

Authors:  Gracjan Różański; Derek Pheby; Julia L Newton; Modra Murovska; Paweł Zalewski; Joanna Słomko
Journal:  Nutrients       Date:  2021-12-26       Impact factor: 5.717

3.  The Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease and Its Association with Physical Function and Prognosis in Patients with Acute Coronary Syndrome.

Authors:  Takumi Noda; Kentaro Kamiya; Nobuaki Hamazaki; Kohei Nozaki; Takafumi Ichikawa; Masashi Yamashita; Shota Uchida; Emi Maekawa; Tasuku Terada; Jennifer L Reed; Minako Yamaoka-Tojo; Atsuhiko Matsunaga; Junya Ako
Journal:  J Clin Med       Date:  2022-03-26       Impact factor: 4.241

4.  Supplementation of Lycium barbarum Polysaccharide Combined with Aerobic Exercise Ameliorates High-Fat-Induced Nonalcoholic Steatohepatitis via AMPK/PPARα/PGC-1α Pathway.

Authors:  Dou-Dou Li; Jia-Min Ma; Ming-Jing Li; Lu-Lu Gao; Yan-Na Fan; Yan-Nan Zhang; Xiu-Juan Tao; Jian-Jun Yang
Journal:  Nutrients       Date:  2022-08-08       Impact factor: 6.706

Review 5.  Exercise Training: The Holistic Approach in Cardiovascular Prevention.

Authors:  Francesco Giallauria; Teresa Strisciuglio; Gianluigi Cuomo; Anna Di Lorenzo; Andrea D'Angelo; Mario Volpicelli; Raffaele Izzo; Maria Virginia Manzi; Emanuele Barbato; Carmine Morisco
Journal:  High Blood Press Cardiovasc Prev       Date:  2021-11-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.